TY - JOUR
T1 - Treatment of essential thrombocythemia with anagrelide
AU - Silverstein, M. N.
AU - Tefferi, A.
PY - 1999
Y1 - 1999
N2 - Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and hemorrhagic complications. Thrombotic complications predominate, endangering especially the older population and those with prior history of thrombotic episodes. However, because the life expectancy of ET patients is generally of normal length, caution must be exercised in treating these patients, and the complications of treatment must be weighed against the complications of the disease. Historically, most drugs used in the treatment of ET, such as alkylating agents and radiophosphorus, were carcinogenic themselves. Even hydroxyurea has recently come under investigation for its long-term mutagenicity. The newest drug, anagrelide, approved in March 1997 specifically for ET, appears to be safe and well tolerated.
AB - Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and hemorrhagic complications. Thrombotic complications predominate, endangering especially the older population and those with prior history of thrombotic episodes. However, because the life expectancy of ET patients is generally of normal length, caution must be exercised in treating these patients, and the complications of treatment must be weighed against the complications of the disease. Historically, most drugs used in the treatment of ET, such as alkylating agents and radiophosphorus, were carcinogenic themselves. Even hydroxyurea has recently come under investigation for its long-term mutagenicity. The newest drug, anagrelide, approved in March 1997 specifically for ET, appears to be safe and well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0032926216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032926216&partnerID=8YFLogxK
M3 - Review article
C2 - 9930554
AN - SCOPUS:0032926216
SN - 0037-1963
VL - 36
SP - 23
EP - 25
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - SUPPL. 2
ER -